The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.

P Sarkar, C Avram, N Chaudhuri

Research output: Contribution to journalArticlepeer-review

Abstract

The approval of two antifibrotic treatment agents for delaying disease progression in idiopathic pulmonary fibrosis (IPF), has prompted researchers to look at expanding the role of antifibrotic therapy to other fibrosing interstitial lung disease (ILD). Similarities in the pathological mechanisms that lead to the development of IPF have been implicated in other progressive fibrosing ILD (PF-ILD) such as chronic hypersensitivity pneumonitis, connective tissues disease associated ILD, sarcoidosis, occupational ILD and idiopathic non-specific interstitial pneumonia (iNSIP). This has prompted the rationale to use antifibrotic therapy to target similar molecular pathways in these diseases.
Original languageEnglish
JournalExpert review of respiratory medicine
DOIs
Publication statusPublished - 6 Jul 2020

Fingerprint

Dive into the research topics of 'The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.'. Together they form a unique fingerprint.

Cite this